# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Balaji Prasad maintains Elanco Animal Health (NYSE:ELAN) with a Overweight and lowers the price target from...
Elanco Animal Health shares drop after updates on FDA approval timelines for Zenrelia and Credelio Quattro. Zenrelia's U.S....
Piper Sandler analyst David Westenberg reiterates Elanco Animal Health (NYSE:ELAN) with a Neutral and raises the price targe...